The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).

Company Growth (employees)
Paris, FR
Size (employees)
203 (est)
Cellectis was founded in 1999 and is headquartered in Paris, FR

Cellectis Office Locations

Cellectis has offices in Paris and New York
Paris, FR (HQ)
8 Rue de la Croix Jarry
New York, US
430 E 29th St

Cellectis Financials and Metrics

Cellectis Financials


Market capitalization (31-Oct-2017)

1.1 b

Closing share price (31-Oct-2017)

Cellectis's current market capitalization is €1.1 b.
Show all financial metrics

Cellectis Market Value History

Cellectis's Web-traffic and Trends

Cellectis Online and Social Media Presence

Cellectis Company Life and Culture

You may also be interested in